One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs

Rheumatology International

Volumn 31, Issue 1, 2011, Pages 33-37

  Giardina, Annarita ^a   Ferrante, Angelo ^a   Ciccia, Francesco ^a   Vadalà, Maria ^a   Giardina, Ennio ^a   Triolo, Giovanni ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Cattedra di Reumatologia   (Italy)

Author keywords

Beh et's disease; Infliximab; TNF alfa

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REMISSION; TACHYCARDIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78751598002     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1213-z     Document Type: Article

References (27)

1. VG Kaklamani G Variopoulos PG Kaklamanis 1998 Behçet's disease Semin Arthritis Rheum 27 197 217 1:STN:280:DyaK1c7ntlSmuw%3D%3D 10.1016/S0049-0172(98)80001-2 9514126 (Pubitemid 28154646)
2. RB Nussenblatt 1997 Uveitis in Behçet's disease Int Rev Immunol 14 67 79 1:STN:280:DyaK2szks1Kisg%3D%3D 9203027
3. Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M, Sakane T (1993) Recent epidemiological features of Behçet's disease in Japan. In: Wechsler B, Godeau P (eds) Behçet's disease. Excerpta Medica, Amsterdam, pp 145-151
4. CC Zouboulis I Kötter D Djawari, et al. 1997 Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe Yonsei Med J 38 411 422 1:STN:280:DyaK1c7ntVKlsA%3D%3D 9509911
5. Dilsen N, Konice M, Aral O, Öcal L, Inanc M, Gill A (1993) Risk factors for vital organ involvement in Behçet's disease. In: Wechsler B, Godeau P (eds) Behçet's disease. Excerpta Medica, Amsterdam, pp 165-169
6. JG Mamo 1970 The rate of visual loss in Behçet's disease Arch Ophthalmol 84 451 452 1:STN:280:DyaE3M%2FnvVGgtg%3D%3D 5492449
7. N Pipitone I Olivieri F Cantini G Triolo C Salvarani 2006 New approaches in the treatment of Adamantiades-Behçet's diseases Curr Opin Rheumatol 18 3 9 1:CAS:528:DC%2BD2MXhtlShtr7P 10.1097/01.bor.0000197995.27579.9b 16344613
8. N Sayinalp OI Ozcebe O Ozdenir IC Haznedaroglu S Dundar S Kirazli 1996 Cytokines in Behçet's disease J Rheumatol 23 321 322 1:STN:280: DyaK2s%2Fjs1eqsw%3D%3D 8882039
9. MA Frassanito R Dammacco P Cafforio F Dammacco 1999 Th1 polarization of the immune response in Behçet's disease: a putative role of interleukin-12 Arthritis Rheum 42 1967 1974 1:CAS:528:DyaK1MXmsl2msLY%3D 10.1002/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z 10513814 (Pubitemid 30257764)
10. G Triolo A Accardo-Palumbo F Dieli F Ciccia A Ferrante E Giardina G Licata 2002 Humoral and cell mediated immune response to cow's milk proteins in Behcet's disease Ann Rheum Dis 61 459 462 1:CAS:528:DC%2BD38Xkt1aktbw%3D 10.1136/ard.61.5.459 11959773 (Pubitemid 34496828)
11. RR Caspi 2002 Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis Int Rev Immunol 21 197 208 1:CAS:528:DC%2BD38XlsVKls7k%3D 10.1080/08830180212063 12424843 (Pubitemid 34791940)
12. G Triolo A Accardo-Palumbo F Dieli F Ciccia A Ferrante E Giardina CD Sano G Licata 2003 Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease Arthritis Res Ther 5 R262 R268 1:CAS:528:DC%2BD3sXmtVeqsLY%3D 10.1186/ar785 12932289
13. M Todaro M Zerilli G Triolo F Iovino M Patti, et al. 2005 NFkB protects Behçet's disease T cells against CD95 induced apoptosis upregulating anti apoptotic proteins Arthritis Rheum 52 2179 2191 1:CAS:528:DC%2BD2MXnsl2gtL4%3D 10.1002/art.21145 15986355 (Pubitemid 40994341)
14. PP Sfikakis PG Theodossiadis CG Katsiari P Kaklamanis NN Markomichelakis 2001 Effect of infliximab on sight-threatening panuveitis in Behcet's disease Lancet 28;358 9278 295 296 10.1016/S0140-6736(01)05497-6 (Pubitemid 32738970)
15. G Triolo M Vadala A Accardo-Palumbo A Ferrante F Ciccia E Giardina P Citarrella G Lodato G Licata 2002 Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease Ann Rheum Dis 61 560 561 1:STN:280:DC%2BD383ms1Cquw%3D%3D 10.1136/ard.61.6.560 12006336 (Pubitemid 34539106)
16. H Al-Rayes R Al-Swallen M Al-Balawi, et al. 2008 Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label study Rheumatol Int 29 53 57 1:CAS:528:DC%2BD1cXhtFOlsLnF 10.1007/s00296-008-0606-8 18496694
17. G Licata A Pinto A Tuttolomondo A Banco F Ciccia A Ferrante G Triolo 2003 Anti-tumor necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome Ann Rheum Dis 62 280 281 1:STN:280:DC%2BD3s7gtl2hsQ%3D%3D 10.1136/ard.62.3.280 12594127 (Pubitemid 36238105)
18. N Pipitone I Olivieri A Padula, et al. 2009 Infliximab for the treatment of neuro-Beheçet's disease: a case series and review of the literature Arthritis Rheum 59 285 290 10.1002/art.23345
19. PH Goossens RJ Verburg FC Bredveld 2001 Remission of Behçet's syndrome with tumour necrosis factor α blocking therapy Ann Rheum Dis 60 637 1:STN:280:DC%2BD3M3lt1ajsw%3D%3D 10.1136/ard.60.6.637 11350856 (Pubitemid 32493994)
20. PV Hassard SW Binder V Nelson EA Vasiliauskas 2001 Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report Gastroenterology 120 995 999 1:STN:280:DC%2BD3M7mtVartw%3D%3D 10.1053/gast.2001.22556 11231954
21. SP Travis M Czajkowski DP McGovern RG Watson AL Bell 2001 Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody Gut 49 725 728 1:STN:280:DC%2BD3MrltlKlug%3D%3D 10.1136/gut.49.5.725 11600479 (Pubitemid 32989213)
22. International Study Group for Behçet's Disease 1990 Criteria for diagnosis of Behçet's disease Lancet 335 995 999
23. BB Bahcta P Brennan TE James A Chamberlain BA Noble AJ Silman 1999 Behçet's disease: evaluation of a new instrument to measure clinical activity Rheumatology 38 728 735 10.1093/rheumatology/38.8.728 (Pubitemid 29507389)
24. G Lawton BB Bahcta AA Chamberlain A Tennant 2004 Behçet's disease activity index Rheumatology 43 73 78 1:STN:280:DC%2BD3sngtVSlug%3D%3D 10.1093/rheumatology/keg453 12890862 (Pubitemid 38088371)
25. DA Jabs RB Nussenblatt JT Rosenbaum 2005 Standardization of uveitis nomenclature (SUN) working group, Standardization of uveitis nomenclature for reporting clinical data Results of the first international workshop Am J Ophtalmol 140 509 516 10.1016/j.ajo.2005.03.057 (Pubitemid 41224845)
26. Hatemi G, Silman A, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Behçet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
27. Y Katsura K Suzukawa H Kojima C Yoshida S Shimizu H Mukai Y Hasegawa S Imagawa N Mori T Nagasawa 2003 Cytotoxic T-cell lymphoma arising in Behcet disease Int J Hematol 77 282 285 10.1007/BF02983787 12731673